Copley Scientific Launches New Products for MDI Testing in Line with the New USP Monograph

Copley Scientific has launched two new products to enable testing in accordance with methods described in a new US Pharmacopoeia (USP) monograph relating to metered dose inhalers (MDIs). The USP monograph, <1602>, which is currently in draft form, addresses the testing of MDIs with spacers and valved holding chambers (VHCs) — devices that make MDIs more suitable for paediatric patients and those with poor co-ordination. The recently launched BAC 2000 breath actuated controller and BRS 1100 breathing simulator, in combination, support closely controlled testing under the representative conditions for neonate, infant, child and/or adult patients outlined in the monograph.
Inexpensive and efficient, MDIs are a popular choice for the delivery of therapeutics for pulmonary conditions. However, the co-ordination required to synchronise operation of an MDI with inhalation inhibits their use by certain patient groups, especially paediatrics. Spacers or VHC s address this issue by introducing a chamber containing dead volume between the MDI and the inhaling patient. The MDI is fired into the spacer or VHC and the patient then inhales freely to draw the drug into the lungs.
The new monograph recognises that the breathing profile of the patient affects their ability to draw the therapeutic aerosol into the lungs, from the spacer or VHC. In addition it highlights the potential variability in drug delivery efficiency arising from the introduction of a time delay between actuation of the MDI and inhalation. New test conditions are outlined, designed to capture the ‘as inhaled’ characteristics of the dose, under representative conditions.
The BAC 2000 is a timer controlled two way solenoid valve. It provides near instantaneous starting and stopping of the air flow during testing and has both delay and inhaled time functions. When testing MDIs in line with the new monograph the delay feature allows sampling of the aerosol from the spacer or VHC to start a defined time after actuation of the MDI. The BAC 2000 can also be useful for controlling the duration for which nebuliser sampling is conducted and for actuating breath-actuated MDIs during testing. It can be used for both dose uniformity testing and for aerodynamic particle size measurement by cascade impaction, where appropriate.
The BRS 1100 is a simple, microprocessor controlled breathing simulator designed to generate the breathing profiles specified by USP and Ph.Eur. for dose uniformity testing of nebulisers and, in the case of the new draft USP monograph, for MDIs with spacers and VHCs. Neonate, infant, child and adult profiles can all be precisely generated by varying tidal volume, frequency, duration and inhalation/exhalation ratio. Starting the breathing cycle at the point of inhalation or exhalation can also be controlled as required for the testing of MDIs with spacers and VHCs, when comparing fully co-ordinated and unco-ordinated use.
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance